Who doesn’t dread hours of testing at a clinic? Innovation needed! Learn about frequent “burst” testing via mobile app, and a digital pen that captures more information than the old paper-and-pencil test.
Presented at CTAD, BACE inhibitor’s efficacy and safety results in mild to moderate AD were encouraging to some clinicians, vaguely disquieting to others.
Ephemeral as they may be, these maligned peptides have become the targets of small-molecule and immunotherapies. Initial results of these efforts to catch and remove Aβ oligomers are trickling in.
Besides the big-gun antibodies and BACE inhibitors, smaller, lesser-known drug programs are inching their way through the clinical trials pipeline. As is often the case, Phase 1 seems encouraging.
Null results ended the development of the neuroprotective drugs edonerpic and abeotaxane, the AMPA receptor modulator S47445, and the dietary formulation tricaprilin.
Tau Snapshots from Neuroscience 2017 Disturbed Sleep Exerts Toll on Memory and Neurodegeneration Gut Microbiome May Modify Neurodegeneration Is There No End to Tau’s Toxic Tricks? This year’s annual meeting drew more than 23,000 scientists and featured 1,
Why, hello tau! Convergence of PET and EEG research affirms that sleeping well is crucial to memory consolidation and curbing Alzheimer’s-related proteins.